Gossamer Bio (GOSS) Total Non-Current Liabilities (2018)
Gossamer Bio (GOSS) posted quarterly Total Non-Current Liabilities of $20.4 million for Q4 2018.
Gossamer Bio (GOSS) Total Non-Current Liabilities (2018) Analysis & Trends
Gossamer Bio's Total Non-Current Liabilities history runs 1 years deep, the most recent figure standing at $20.4 million for Q4 2018.
- In Q4 2018, Total Non-Current Liabilities changed N/A year-over-year to $20.4 million; the TTM figure through Dec 2018 stood at $20.4 million (changed N/A YoY), while the FY2018 annual figure was $20.4 million, changed N/A from the prior year.
- Total Non-Current Liabilities for Q4 2018 stood at $20.4 million.
- The five-year high for Total Non-Current Liabilities was $20.4 million in Q4 2018, with the low at $20.4 million in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.17 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.32 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 724.15 Mn |
| 10 | Gossamer Bio | 50.34 Mn | -6.69 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 20.40 Mn |